Connect
MJA
MJA

Recent increase in detection of alprazolam in Victorian heroin-related deaths

Angela C Rintoul, Malcolm D H Dobbin, Suzanne Nielsen, Louisa Degenhardt and Olaf H Drummer
Med J Aust 2013; 198 (4): 206-209. || doi: 10.5694/mja12.10986
  • Angela C Rintoul1
  • Malcolm D H Dobbin2
  • Suzanne Nielsen3
  • Louisa Degenhardt4
  • Olaf H Drummer5

  • 1 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC.
  • 2 Mental Health, Drugs and Regions Division, Department of Health, Victoria, Melbourne, VIC.
  • 3 Discipline of Addiction, University of Sydney, Sydney, NSW.
  • 4 National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW.
  • 5 Department of Forensic Medicine, Monash University, Melbourne, VIC.

Correspondence: angela.rintoul@monash.edu

Acknowledgements: 

We are grateful to Damien Jolley and Rory Wolfe of Monash University for providing statistical advice; the PBAC Drug Utilisation Sub-Committee for extracting ASM national prescription volume data; and Katayoon Yazdani for assisting in the compilation of Medicare Australia data.

Angela Rintoul is currently funded through an Australian Postgraduate Award scholarship. Some of this work was completed during her participation in the Victorian Public Health Training Scheme, funded by the State of Victoria through the Department of Health, while on placement with the Drugs Policy Unit at the Victorian Department of Health.

The views and conclusions in this article are ours and do not necessarily represent those of the Department of Health.

Competing interests:

Suzanne Nielsen has worked in an unpaid capacity as an investigator on projects funded by untied educational grants from Reckitt-Benckiser (RB). She has not received any direct funding. Louisa Degenhardt has received untied educational grants from RB to undertake postmarketing surveillance of suboxone tablet and film products in Australia. Malcolm Dobbin has received an honorarium from Pfizer for lectures, which was donated to charity. Neither RB nor Pfizer had knowledge of, or input into, this paper.

  • 1. Horyniak D, Reddel S, Quinn B, Dietze P. The use of alprazolam by people who inject drugs in Melbourne, Australia. Drug Alcohol Rev 2012; 31: 585-590.
  • 2. Chen KW, Berger CC, Forde DP, et al. Benzodiazepine use and misuse among patients in a methadone program. BMC Psychiatry 2011; 11: 90. doi: 10.1186/1471-244X-11-90.
  • 3. Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend 2012; 125: 8-18.
  • 4. Lader M. Benzodiazepines revisited — will we ever learn? Addiction 2011; 106: 2086-2109.
  • 5. Kirwan A, Dietze P, Lloyd B. Victorian drug trends 2011: findings from the Illicit Drug Reporting System (IDRS). Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2012. http://ndarc.med.unsw.edu.au/sites/ndarc.cms.med.unsw.edu.au/files/ndarc/resources/VIC_IDRS_2011.pdf (accessed Nov 2012).
  • 6. Dietze P, Jolley D, Fry C, Bammer G. Transient changes in behaviour lead to heroin overdose: results from a case-crossover study of non-fatal overdose. Addiction 2005; 100: 636-642.
  • 7. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction 1999; 94: 961-972.
  • 8. Moylan S, Giorlando F, Nordfjaern T, Berk M. The role of alprazolam for the treatment of panic disorder in Australia. Aust N Z J Psychiatry 2012; 46: 212-224.
  • 9. Isbister GK, O’Regan L, Sibbritt D, Whyte IM. Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol 2004; 58: 88-95.
  • 10. Nielsen S, Lintzeris N, Lee N, et al. Pharmacodynamic interactions of alprazolam in methadone and buprenorphine naloxone patients [abstract for oral communication]. College on Problems of Drug Dependence 70th Annual Scientific Meeting; 2008 Jun 14–19; San Juan, Puerto Rico. http://www.cpdd.vcu.edu/Pages/Meetings/CPDD08AbstractBook2.pdf (accessed Nov 2012).
  • 11. Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: interactions a nd clinical management. Am J Addict 2010; 19: 59-72.
  • 12. Jenkinson R, O’Keeffe B. Victorian drug trends 2005: findings from the Illicit Drug Reporting System (IDRS). National Drug and Alcohol Research Centre Technical Report No. 256. Sydney: NDARC, University of New South Wales, 2006. http://ndarc.med.unsw.edu.au/sites/ndarc.cms.med.unsw.edu.au/files/ndarc/resources/TR.256.pdf (accessed Nov 2012).
  • 13. Drugs and Crime Prevention Committee. Inquiry into the impact of drug-related offending on female prisoner numbers — interim report. Melbourne: Parliament of Victoria, 2010.
  • 14. McIlwraith F, Hickey S, Alati R. Benzodiazepine update: alprazolam and other benzodiazepine use among people who inject drugs. Illicit Drug Reporting System Drug Trends Bulletin, April 2012. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2012. http://ndarc.med.unsw.edu.au/sites/ndarc. cms.med.unsw.edu.au/files/ndarc/resources/IDRS%20April%202012.pdf (accessed Nov 2012).
  • 15. Darke S, Ross J, Mills K, et al. Benzodiazepine use among heroin users: baseline use, current use and clinical outcome. Drug Alcohol Rev 2010; 29: 250-255.
  • 16. Rose G, Day S. The population mean predicts the number of deviant individuals. BMJ 1990; 301: 1031-1034.
  • 17. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2012. http://www.whocc.no/atc_ddd_index/ (accessed Nov 2012).
  • 18. Verster JC, Volkerts ER. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Rev 2004; 10: 45-76.
  • 19. Rose G., Khaw KT, Marmot M. Rose’s strategy of preventive medicine. New York: Oxford University Press, 2008.
  • 20. Degenhardt L, Day C, Gilmour S, Hall W. The “lessons” of the Australian “heroin shortage”. Subst Abuse Treat Prev Policy 2006; 1: 11.
  • 21. Wolf BC, Lavezzi WA, Sullivan LM, et al. Alprazolam-related deaths in Palm Beach County. Am J Forensic Med Pathol 2005; 26: 24-27.
  • 22. Therapeutic Goods Administration. National Drugs and Poisons Schedule Committee. Record of reasons. 59th meeting, 22–23 June 2010. Canberra: Department of Health and Ageing: 98-110. http://www.tga.gov.au/pdf/archive/ndpsc-record-59.pdf (accessed Apr 2012).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.